GSA Capital Partners’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-110,500
| Closed | -$1.24M | – | 1986 |
|
|
2017
Q3 | $1.24M | Sell |
110,500
-56,613
| -34% | -$624K | 0.08% | 381 |
|
|
2017
Q2 | $1.84M | Sell |
167,113
-72,900
| -30% | -$729K | 0.12% | 190 |
|
|
2017
Q1 | $2.35M | Buy |
240,013
+8,799
| +4% | +$87.9K | 0.13% | 194 |
|
|
2016
Q4 | $2.5M | Buy |
231,214
+29,701
| +15% | +$297K | 0.15% | 139 |
|
|
2016
Q3 | $2.07M | Sell |
201,513
-7,600
| -4% | -$82.8K | 0.11% | 233 |
|
|
2016
Q2 | $2.73M | Sell |
209,113
-103,002
| -33% | -$1.35M | 0.15% | 128 |
|
|
2016
Q1 | $3.43M | Sell |
312,115
-13,000
| -4% | -$116K | 0.22% | 45 |
|
|
2015
Q4 | $2.99M | Buy |
325,115
+54,227
| +20% | +$454K | 0.15% | 124 |
|
|
2015
Q3 | $1.88M | Sell |
270,888
-135,114
| -33% | -$1.16M | 0.09% | 291 |
|
|
2015
Q2 | $3.99M | Buy |
406,002
+60,169
| +17% | +$548K | 0.15% | 88 |
|
|
2015
Q1 | $3.06M | Buy |
345,833
+184,544
| +114% | +$1.47M | 0.12% | 151 |
|
|
2014
Q4 | $1.41M | Buy |
161,289
+41,363
| +34% | +$335K | 0.1% | 272 |
|
|
2014
Q3 | $826K | Sell |
119,926
-9,981
| -8% | -$59.8K | 0.04% | 611 |
|
|
2014
Q2 | $683K | Buy |
129,907
+13,417
| +12% | +$65.3K | 0.03% | 933 |
|
|
2014
Q1 | $530K | Sell |
116,490
-6,204
| -5% | -$30K | 0.04% | 740 |
|
|
2013
Q4 | $618K | Buy |
122,694
+12,352
| +11% | +$59.4K | 0.05% | 677 |
|
|
2013
Q3 | $559K | Buy |
110,342
+64,529
| +141% | +$359K | 0.04% | 718 |
|
|
2013
Q2 | $227K | Buy |
+45,813
| New | +$218K | 0.03% | 1025 |
|
GSA Capital Partners's SCLN Position: Q4 2017 in Review
GSA Capital Partners sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 110,500 shares — an estimated $1.24M sold.
GSA Capital Partners first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $3.99M in Q2 2015. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- GSA Capital Partners reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- GSA Capital Partners sold 110,500 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.24M.
- GSA Capital Partners first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- GSA Capital Partners's Sciclone Pharmaceuticals Inc position peaked at $3.99M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on GSA Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.